<<<<<<
><br>
Cychlorphine: An Emerging Synthetic Opioid Requiring Immediate Clinical Attention<br>
>>>>>>>TITLE<br>
<
p>Recent surveillance reveals a surge in the synthetic opioid cychlorphine (N‑propionitrile chlorphine) that has prompted significant concern among physicians and public health officials.
<p>The street drug has been linked to at least fifty‑five fatalities nationwide between 2025 and 2026, according to a “drug threat notice” issued by the Office of National Drug Control Policy (ONDCP) in April. Its prevalence appears most pronounced in Ohio, Tennessee, and Texas.</p>
<p>Cychlorphine belongs to the orphine subclass of opioids and shares structural features with related benzimidazolone compounds such as brorphine and chlorphine.</p>
<p>Jon E. Sprague, PhD, of Bowling Green State University in Ohio, highlighted several critical knowledge gaps regarding orphines during his interview with MedPage Today. He emphasized, “We lack precise data on human potency. Duration of effect remains uncertain. Metabolic pathways are unclear. And how rapidly the compound traverses the central nervous system are questions that remain unanswered.”</p>
<p>Cychlorphine surfaced on the streets between mid‑2024 and late 2025. Sprague observed that following China’s July 2025 crackdown on nitazene analogues, the compound entered illicit circulation as suppliers pivoted to fill the void.</p>
<p>“They’re engineering novel molecular scaffolds at unprecedented speed, leaving a scarcity of information on these substances before they reach patients,” Sprague remarked.</p>
<p>While newer, the predecessors are not unknown. Earlier orphine derivatives were developed in the 1960s as experimental analgesics, yet never reached commercial release—likely due to heightened agonist activity at mu receptors, Sprague explained.</p>
<p>A detailed case report co‑authored by Sprague describes a nonfatal incident in which a 36‑year‑old male was discovered unconscious and revived with naloxone after allegedly intranasally consuming a substance he mistook for alprazolam. Although the patient declined to submit urine or blood specimens, a sealed container containing a pale tan crystalline residue was collected at the location. Subsequent analysis revealed the presence of fentanyl, xylazine, and cychlorphine within the material. The forensic team in Ohio required weeks to confirm the identity of the adulterant.</p>
<p>A separate case series released earlier this year involved a young adult woman who expired after apparently overdosing on a pill she falsely thought was alprazolam. She received rapid nasogastric naloxone and was transported to emergency services. Comprehensive toxicology panel results confirmed cychlorphine alongside bromazolam, carboxy‑THC, acetaminophen, caffeine, citalopram, cotinine, naloxone, naproxen, nicotine, and the sedative‑trauma‑inducing agent trazodone together with its metabolites.</p>
<p>MD Rebecca Kusko, a co‑author of the paper, underscored that conventional screening panels often fail to flag unrecognized opioids, yet treatment with naloxone remains warranted when clinical suspicion of narcotic ingestion persists.</p>
<p>Cychlorphine predominantly manifests as a powder or tablet formulation, including counterfeit medication units. Accommodations include snorting and inhalation, while oral ingestion and intravenous routes are also plausible, according to Dr. Shravani Durbhakula, MD, MPH, of Vanderbilt University Medical Center in Nashville.</p>
<p>Within Knox County, the Regional Forensic Center recorded forty‑one overdose fatalities spanning July 2025 to February 2026. Durbhakula noted that the facility subsequently documented up to sixty‑three cychlorphine‑related deaths by late June, placing the substance among the top four causes of mortality in the period—a striking trend emerging only months after initial identification.</p>
<p>Chief Administrative Officer Chris Thomas corroborated the tally, affirming that cychlorphine accounted for roughly fifty‑eight of the sixty‑three deaths and was the primary culprit in a substantial portion of cases. His assessment warned that the drug can be extremely lethal even at minute doses.</p>
<p>ONDCP guidance indicates the compound could rival or surpass fentanyl in potency, suggesting that a single administration may demand repeat naloxone dosing; nevertheless, Durbhakula emphasized that these quantitative claims stem primarily from laboratory pharmacology rather than human dose‑response experiments.</p>
<p>««Although popular narratives claim naloxone is ineffective, this broad statement misrepresents clinical reality,» stated Lewis Nelson, MD, a medical toxicologist at Charles E. Schmidt College of Medicine, Florida Atlantic University in Boca Raton. He urged caregivers to prioritize immediate airway protection, emphasizing that ventilatory recovery must take precedence over any expectation of the dramatic reversal depicted in television broadcasts.”””</p>
<p>The ultimate objective of successful naloxone therapy is respiratory stabilization—not merely achieving consciousness, » Nelson explained.</p>
<p>»Dispersed epidemiology conceals concentration trends, since many public‑health agencies, hospitals, and median examinations rarely incorporate cychlorphine into preanalytic processing,» Durbhakula warned.»</p>
<p>Concerned about the confluence of extreme potency and diagnostic invisibility, the expert cautioned clinicians that a negative opioid screen—even for typical opioids—does not exclude exposure to synthetic alternatives like cychlorphine.</p>
<p><<</p><title>><br>
<br>
<div class="also-read-section amp-wp-70dc194" data-amp-original-style="margin: 40px 0; padding: 20px; background: #f9f9f9; border-left: 4px solid #e74c3c;">
<h3 data-amp-original-style="margin-top: 0; color: #333;" class="amp-wp-de18dc4">Also Read</h3>
<ul data-amp-original-style="list-style: none; padding: 0; margin: 0;" class="amp-wp-23c7e5e">
<li data-amp-original-style="margin-bottom: 12px;" class="amp-wp-7b754ee">
<a href="https://globalindepth.com/democratic-lawmakers-urge-halt-on-federal-program-collecting-emergency-room-patient-data/?amp=1" data-amp-original-style="text-decoration: none; color: #1e3a8a; font-weight: 500;" class="amp-wp-cfdda47">
Democratic Lawmakers Urge Halt on Federal Program Collecting Emergency Room Patient Data </a>
</li>
<li data-amp-original-style="margin-bottom: 12px;" class="amp-wp-7b754ee">
<a href="https://globalindepth.com/stat-astrazenecas-experimental-copd-treatment-posts-strong-results-in-late-stage-studies/?amp=1" data-amp-original-style="text-decoration: none; color: #1e3a8a; font-weight: 500;" class="amp-wp-cfdda47">
STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies </a>
</li>
<li data-amp-original-style="margin-bottom: 12px;" class="amp-wp-7b754ee">
<a href="https://globalindepth.com/second-rsv-dose-for-seniors-remains-unanswered-as-reviewers-cite-evidence-gaps/?amp=1" data-amp-original-style="text-decoration: none; color: #1e3a8a; font-weight: 500;" class="amp-wp-cfdda47">
Second RSV Dose for Seniors Remains Unanswered as Reviewers Cite Evidence Gaps </a>
</li>
<li data-amp-original-style="margin-bottom: 12px;" class="amp-wp-7b754ee">
<a href="https://globalindepth.com/novartis-neuromuscular-drug-fails-pivotal-trial-escalating-pipeline-pressures/?amp=1" data-amp-original-style="text-decoration: none; color: #1e3a8a; font-weight: 500;" class="amp-wp-cfdda47">
Novartis neuromuscular drug fails pivotal trial, escalating pipeline pressures </a>
</li>
</ul>
</div>
<p><a href="https://www.medpagetoday.com/publichealthpolicy/opioids/122919">Source link </a></p>
